Carla Nieser

Sapient is an end-to-end biomarker discovery partner providing solutions from large-scale untargeted discovery screening through development of targeted, quantitative CLIA assays to support drug programs at every phase. Our platform combines advanced mass spectrometry technologies – able to assay >11,000 small molecule biomarkers per biosample – computational learning, and an expansive proprietary Human Biology Database of several hundred thousand biosamples to discover small molecule biomarkers at unprecedented speed and scale, and rapidly deliver actionable insights that align patients, disease biology, and specific therapies.